IMMUNITYBIO, INC.

Analyst Reco. ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Market Closed - Nasdaq Other stock markets 21:00:00 26/06/2024 BST			5-day change	1st Jan Change
6.77 ^USD	-6.88%		+8.67%	+34.86%

06-20	Sector Update: Health Care Stocks Mixed Thursday Afternoon	MT
06-20	ImmunityBio Shares Rise After Launch of Bladder Cancer Treatment Anktiva in US	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	05-06	MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline	05-03	MT
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline	04-30	MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating	04-29	MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	04-29	MT
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating	03-25	MT
Piper Sandler Downgrades ImmunityBio to Neutral From Overweight, Cuts Price Target to $4 From $10	12/05/23	MT
Jefferies Starts ImmunityBio at Buy With $8 Price Target	03/08/22	MT
Piper Sandler Adjusts ImmunityBio's Price Target to $10 From $20, Reiterates Overweight Rating	31/05/22	MT
ImmunityBio : Says Phase 2/3 Trial in BCG-Unresponsive Bladder Cancer Patients Achieves Complete Response Rate of 72%	13/09/21	MT
ImmunityBio, Inc. Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with A Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 Trial	13/09/21	CI
Nantkwest : Reports Positive Interim Data on Survival Rates from Pivotal Pancreatic Cancer Trials; Shares Hit New 52-Week High	14/01/21	MT
NantKwest, Inc. and ImmunityBio, Inc. Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials	13/01/21	CI
ImmunityBio, Inc. Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate	21/12/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer